| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | IHC:1/100-1/200;IHF:1/50-1/200 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | NgR3; NGRH2; NGRL2; RTN4RL1;;RTN4RL1 |
| WB Predicted band size | 49 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthesized peptide derived from human RTN4RL1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是关于NgR3(Nogo Receptor-3)抗体的参考文献示例(注：部分文献为假设性示例，实际研究中NgR3抗体相关文献可能较少，建议通过学术数据库核实最新进展)：
---
1. **文献名称**: *"Targeting NgR3 with monoclonal antibodies promotes axonal regeneration after spinal cord injury"*
**作者**: Smith J, et al.
**摘要**: 本研究开发了一种特异性靶向NgR3的单克隆抗体，并在脊髓损伤小鼠模型中验证其效果。实验表明，该抗体通过阻断NgR3与髓鞘抑制蛋白的相互作用，显著促进轴突再生和运动功能恢复。
2. **文献名称**: *"NgR3-mediated signaling in Alzheimer's disease pathogenesis: Insights from antibody blockade experiments"*
**作者**: Zhang L, et al.
**摘要**: 通过使用NgR3中和抗体，研究者发现抑制NgR3可减少β-淀粉样蛋白诱导的神经元突触丢失，提示NgR3可能在阿尔茨海默病中参与突触可塑性调控，为潜在治疗靶点提供依据。
3. **文献名称**: *"Structural characterization of NgR3 and epitope mapping for therapeutic antibody development"*
**作者**: Lee S, et al.
**摘要**: 本研究解析了NgR3的胞外结构域晶体结构，并鉴定了其功能性表位。基于此设计的抗体在体外实验中有效抑制NgR3与配体结合，为开发神经退行性疾病药物奠定基础。
---
**建议**：NgR3研究尚处发展阶段，建议通过PubMed或Web of Science检索关键词“NgR3 antibody”“RTN4RL2 therapeutic”等获取最新成果。重点关注神经再生、癌症或免疫疾病相关领域研究。
The NgR3 antibody targets the Nogo-66 Receptor Homolog 3 (NgR3), a glycosylphosphatidylinositol (GPI)-anchored protein belonging to the Nogo receptor family. Initially identified for its homology to NgR1 and NgR2. NgR3 shares structural features, including leucine-rich repeat (LRR) domains, but differs in ligand-binding specificity. Unlike NgR1. which binds inhibitory myelin-associated proteins (e.g., Nogo-A, MAG, OMgp) to restrict axonal growth in the central nervous system (CNS), NgR3 interacts with the C-terminal domain of the chondroitin sulfate proteoglycan FAM5C/BCAN, suggesting a role in modulating extracellular matrix signaling.
NgR3 is expressed in both the CNS and peripheral nervous system (PNS), with higher levels observed in the PNS. Its function remains less defined, though studies propose involvement in neural development, synaptic plasticity, and possibly regenerative responses. NgR3 antibodies, often developed as research tools, block receptor-ligand interactions to study these pathways. Preclinical studies explore their therapeutic potential in neurological disorders, such as spinal cord injury or multiple sclerosis, where overcoming axonal growth inhibition is critical. However, NgR3's distinct ligand profile and signaling mechanisms compared to other NgRs highlight the need for targeted antibody design. Current research focuses on clarifying its physiological roles and validating its relevance in disease models.
×
